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Abstract
IMPORTANCE Increasing evidence indicates that acute kidney injury (AKI) occurs frequently in
children and young adults and is associated with poor short-term and long-term outcomes. Guidance
is required to focus efforts related to expansion of pediatric AKI knowledge.

Key Points
Question What are the clinical care,
education, research and advocacybased priorities for acute kidney injury
(AKI) in children and young adults?

OBJECTIVE To develop expert-driven pediatric specific recommendations on needed AKI research,

Findings In this consensus statement, a

education, practice, and advocacy.

panel of 46 global experts developed
pediatric AKI specific consensus state-

EVIDENCE REVIEW At the 26th Acute Disease Quality Initiative meeting conducted in November

ments regarding epidemiology, diagnos-

2021 by 47 multiprofessional international experts in general pediatrics, nephrology, and critical care,

tics, mechanical support, educational

the panel focused on 6 areas: (1) epidemiology; (2) diagnostics; (3) fluid overload; (4) kidney support

goals, and biologic and physiologic devel-

therapies; (5) biology, pharmacology, and nutrition; and (6) education and advocacy. An objective

opment of the growing child. In addition

scientific review and distillation of literature through September 2021 was performed of (1)

gaps in knowledge and areas for further

epidemiology, (2) risk assessment and diagnosis, (3) fluid assessment, (4) kidney support and

research were identified.

extracorporeal therapies, (5) pathobiology, nutrition, and pharmacology, and (6) education and
advocacy. Using an established modified Delphi process based on existing data, workgroups derived
consensus statements with recommendations.

Meaning Focused and coordinated
efforts, integrating AKI specialists and
researchers with the general medical
community and population, may

FINDINGS The meeting developed 12 consensus statements and 29 research recommendations.
Principal suggestions were to address gaps of knowledge by including data from varying
socioeconomic groups, broadening definition of AKI phenotypes, adjudicating fluid balance by
disease severity, integrating biopathology of child growth and development, and partnering with
families and communities in AKI advocacy.
CONCLUSIONS AND RELEVANCE Existing evidence across observational study supports further
efforts to increase knowledge related to AKI in childhood. Significant gaps of knowledge may be
addressed by focused efforts.
JAMA Network Open. 2022;5(9):e2229442. doi:10.1001/jamanetworkopen.2022.29442

improve short-term and long-term
outcomes for children and young adults
with AKI in the areas of disease
awareness, diagnostics, recognition,
management, and follow-up.
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Introduction
The pediatric acute kidney injury (AKI) research field has expanded during the past decade with
international epidemiologic studies, long-term AKI follow-up studies, validation of AKI prediction
models, and continued investigation of novel AKI biomarkers.1-9 The 26th Acute Disease Quality
Initiative (ADQI XXVI) convened in Napa, California, in November 2021, the first Pediatric ADQI
(pADQI) that specifically addressed the global burden of AKI in the child and young adult population,
with focused attention paid to kidney development and AKI, prenatal or neonatal kidney physiology,
dialysis devices engineered for children,10 and the unique aspects of pediatric AKI epidemiology. The
pADQI was assembled to mirror the global workforce in pediatrics and used a public and patientfacing approach. The primary aim of the pADQI was to identify the work priorities across the pediatric
AKI landscape of care, education, research, and advocacy.

Methods
The pADQI consensus meeting followed the established ADQI process, as previously described,11 to
provide expert-based statements and interpretation of current knowledge for use by clinicians
according to professional judgment and identify evidence care gaps to establish research priorities.
We performed an objective scientific review and distillation of literature through September 2021 of
(1) epidemiology, (2) risk assessment and diagnosis, (3) fluid assessment, (4) kidney support and
extracorporeal therapies, (5) pathobiology, nutrition, and pharmacology, and (6) education and
advocacy. The 6 workgroups were composed of representatives from 5 continents of varying age
(median: 43 years; range, 24-74 years), gender (23 male, 23 female) and professional discipline
(physicians, nurses, pharmacists, and nutritionists). In addition, a pediatric patient survivor of AKI
and an expert in equity and care delivery were included in the pADQI and assisted all workgroups.
The in-person meeting was conducted using workgroups and large group in mixed in-person and
virtual (72% in person) formats. Work following the in-person meeting was completed virtually.
Using a modified Delphi method, each workgroup determined key questions supported by
representative literature, or professional opinion when evidence was scarce, and presented their
drafts iteratively to develop consensus statements (target of 2-3 per group) (main document), and to
articulate a research agenda with a more comprehensive background (Table; eBackground and eBox
in the Supplement). The consensus statements were categorized as recommendations or
suggestions. The work product was finalized and approved by the entire group in 2 follow-up
web-based meetings. This summary statement was based on existing evidence in the literature, thus
institutional approval was not required. All members of pADQI consented to their inclusion in this
article. The statements are presented herein as direct quotations.

Table. Consensus-Derived Considerations to Address Knowledge Gaps for Children and Young Adults With Acute Kidney Injury
Paradigm

Consensus

Knowledge gap and needed work

Epidemiology

• Stratified understanding of high risk:
Neonates, heart disease, chronic kidney disease, sepsis, cystic fibrosis, transplant history,
oncologic history, chronic liver disease

• Middle- and low-income populations
• Expanded AKI phenotypes

Diagnostics

• Biomarker-based delineation of standard vs high risk

• Integration of concurrent diagnostics
• Differentiation of diagnostics over time

Fluid balance

• Use of percent fluid balance and anchor weight (ICU admission weight)

• Adjudicate “fluid overload” by illness state

KST

• Institute benchmarks and components of KST team
• Need for pediatric specific extracorporeal therapies

• KST team, quality, and cost optimization
• KST integration of tandem therapies

Biopathology

• Pediatrics incorporated into research efforts
• Importance of nephrotoxin stewardship programs
• Promoting bench-bedside collaboration between preclinical, epidemiological
and clinical trial researchers

• Determination of sex as a biological variable related to AKI
• Characterize medications affected by AKI across
developmental spectrum
• Identify the optimal nutritional interventions by age for
AKI

Education and
advocacy

• Differential approach based on national resources
• Integration of electronic medical record/checklists

• Governmental and community partnerships
• Cross-discipline health care training

Abbreviations: AKI, acute kidney injury; ICU, intensive care unit; KST, kidney support therapy.
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The age spectrum of patients receiving the care of pediatric specialists ranged from extremely
low birthweight neonates to young adults. Throughout this manuscript, the terms child, children, and
pediatric reflect the entire age spectrum, unless specifically noted.

Group 1: What Will Drive the Continuing Refinement and Evolution
of AKI Epidemiology?
Consensus Statement 1A (Recommendation)
• AKI epidemiology related to short-term outcomes is well-described in critically ill neonates and
children from high-income countries; however, further study is needed in other health care
contexts, such as low-middle income countries and in non-ICU and ambulatory settings and for
socioeconomic and long-term outcomes.
Consensus Statement 1B (Suggestion)
• An understanding of pediatric AKI epidemiology allows us to begin employing strategies to improve
primary, secondary, and tertiary AKI prevention in at-risk patient groups.
Implementation of standardized criteria to define the presence and severity of AKI has facilitated a
description of pediatric AKI epidemiology.11-14 Prospective multicenter studies provide insight into
the epidemiology of AKI in critically ill neonates and children.1,2 Other studies describe AKI
epidemiology in specific cohorts of children including sepsis,15 those receiving nephrotoxins,16 and
cardiac surgical populations.17,18 However, residual knowledge gaps remain regarding the accurate
description of AKI epidemiology in other health care contexts as the most data come from highincome countries, and few studies have described AKI epidemiology outside critical care settings.
Pediatric literature has described AKI and morbidity, mortality, and health resource use in
critically ill children with a gradient-response association between AKI severity and the risk of worse
outcomes.1,19,20 More recently, research has focused on assessing the medium and long-term
sequalae of AKI, including longitudinal kidney function and its socioeconomic outcomes.16,21,22
A comprehensive description of pediatric AKI epidemiology reflects current practice and best
available information (eFigure 1 in the Supplement). Given this, information should be up to date and
readily available to clinicians and institutions in real time. A risk prediction study23 and a randomized
clinical trial24 suggest a causal link between pediatric AKI and a limited scope of short-term
outcomes, supporting prevention and mitigation of pediatric AKI and its complications as targets for
improving outcomes. Pediatric AKI epidemiologic characteristics can be categorized as pre-event
(eg, risk factors, key drivers, and predictors), peri-event (eg, demographic characteristics and
etiology), and postevent (eg, outcomes and recovery). Studies of AKI epidemiology should explore
the temporal nature of AKI, health contexts (eg, populations and locations) in which AKI has been
inadequately described, and outcomes that are focused on patient, family, cost, and performance.
Thus, by following epidemiologic trends, clinicians can help focus efforts to enhance public health
surveillance, augment field investigations, clinical and preclinical studies, and further policy
development to promote child health (eBox and eBackground in the Supplement).

Group 2: What Are the Unique Considerations for AKI Risk Stratification and Diagnosis
in Children?
Consensus Statement 2A (Recommendation)
• Validated tools which incorporate patient characteristics and exposure and also interface with the
local health care environment should be utilized to estimate AKI risk in children, including
assessment of objective measures of kidney fitness in at-risk children prior to a predictable or
planned intervention.
Consensus Statement 2B (Suggestion)
• Unique AKI phenotypes in children may overlap and change over time. Differentiating AKI
phenotype(s) informs prognosis and has the potential to guide therapeutics.
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Previous studies1,25-28 identified baseline patient characteristics and exposures that place children at
increased risk for AKI, including but not limited to cancer therapy, cardiopulmonary bypass,
extracorporeal membrane oxygenation, major surgical procedures, and a high nephrotoxic
medication burden.1,26,29 Integrating diagnostic resources may optimize AKI risk assessment for
high-risk diagnoses (eg, by using point-of-care testing and automated algorithms) or exposures (eg,
by using the electronic medical record) could be updated continuously in real time30 (Figure 1A31).
Prior to a planned exposure associated with increased AKI risk, ascertainment of kidney fitness
using traditional measures of kidney function and damage, including serum creatinine and cystatin
C levels, and urine albumin or protein level can be used to direct comprehensive kidney protection
and surveillance and prevent AKI development.32 Preoperative values of candidate biomarkers may
have utility in predicting AKI after cardiac surgery in adults and children.33-35 Kidney functional
reserve values can predict postoperative AKI in adults.36 (Figure 1A31).
When available, biomarkers that indicate structural kidney injury may provide further insight
into AKI risk and phenotype.37 For example, structural biomarker concentration elevation in the
absence of functional biomarker elevation may indicate early kidney injury that is not readily
reversible. Conversely, functional biomarker elevation alone may be indicative of decreased effective
circulating volume and direct care toward restoration of volume. The terms functional AKI and
structural AKI, to supplant the terms pre-renal AKI and intrinsic AKI were first proposed by the ADQI
X Consensus Conference.38 Single center pediatric study and systematic reviews provide initial
validation of these concepts, with structural AKI being associated with worse outcomes than
functional AKI alone.39-41

Figure 1. Acute Kidney Injury (AKI) Risk Assessment and Dynamic Phenotyping
A AKI risk assessment

Risk assessment

Heterogeneous
population of children

B

Routine care
• Repeat risk assessment with clinical changes

Standard risk for AKI

• Patient factors
• Disease factors
• Event factors
• Renal fitness

Kidney-focused care
• Comprehensive kidney protection and surveillance
• Targeted biomarker measurement
• Informed clinical trial enrollment

High risk for AKI

Dynamic AKI phenotyping

Serum
creatinine
Biomarkers

Unknown
factors

Dynamic AKI
phenotypes

Urine
output

Fluid
overload

Ongoing
assessment

Prognostic implications

Timing

Big data

Therapeutic implications
Patient with
undifferentiated AKI

Diuretic
response

Patient with differentiated
AKI phenotypes

Duration
Severity

A, AKI risk assessment should occur in children with a potential kidney insult or any
clinical changes to stratify patients into those at standard or high risk for AKI such that
kidney-focused care can be implemented. B, Combined with individual susceptibility,
multiple elements contribute to discernible AKI phenotypes in affected children that

may have prognostic and therapeutic implications. Adapted from the 26th Acute Disease
Quality Initiative31 with permission. These are open access images distributed under the
terms of the Creative Commons Attribution License.
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Pediatric AKI is a heterogeneous disease with multiple etiologic factors, biochemical signatures,
and clinical manifestations. Expert consensus and emerging data support the view that these
elements combined with individual susceptibility contribute to unique, discernible AKI phenotypes
in children with AKI (Figure 1B31). In particular, evidence supports the use of clinical features such as
urine output,42,43 severity and duration of creatinine elevation,44,45 fluid overload,46 response to
loop diuretics,47,48 and tubular injury biomarkers,39,41 to refine AKI diagnosis and reveal unique
phenotypes. The concept of subclinical AKI is defined by an elevation in a urine tubular injury
biomarker without elevation in functional marker. Subclinical AKI is associated with worse outcomes
in children without AKI or with functional AKI.39,41 Although these studies examined static 1 or 2
factor-based AKI phenotypes, it is likely that more than 1 of these discernible phenotypes may be
present in a child with AKI at a given time and that this unique phenotypic signature is dynamic
(Figure 1B31). A dynamic diagnostic model to address a dynamic phenotype, akin to blood gas
assessment in acute lung injury, may be required for AKI (eBox and eBackground in the Supplement).

Group 3: What Considerations Are Needed for Fluid Assessment in Sick Children?
Consensus Statement 3A (Recommendation)
• Fluid balance is the difference between total input and output that can be expressed as “daily”
and/or “cumulative” over a defined duration of time.
Consensus Statement 3B (Suggestion)
• Fluid overload denotes a pathologic state of positive fluid balance associated with a clinically
observable event(s), which may vary by age, case-mix, acuity, and phase of illness. No specific
threshold of positive fluid balance alone can define fluid overload across all sick children.
As with AKI diagnosis, consistent use of consensus terminology is essential to further our
understanding of fluid management and outcomes. Many terms have been used imprecisely to
assess the impact of fluid volume on outcomes in sick children, including fluid balance, fluid
accumulation, and fluid overload. Fluid overload has been conflated to describe both the degree of
positive fluid balance within a patient and its association with adverse outcomes.49-55 Use of the
term in this manner introduces bias into research and clinical practice, as it presumes any degree of
positive fluid balance is synonymous with fluid overload and is therefore detrimental. Moreover, such
use presumes that net fluid removal and targeting negative fluid balance is beneficial. Fluid overload
is a distinct pathologic state of positive fluid balance with adverse consequences. Fluid balance is an
objective calculation using specific methods. We suggest that the term percent cumulative fluid
balance be used to describe the previously referred term, percent fluid overload,56 to separate the
pathologic state from specific calculations. The terms daily fluid balance, cumulative fluid balance,
and percent cumulative fluid balance describe fluid status of patients for purpose of clinical care and
research (eTable 1 in the Supplement) more precisely.
The 2 methods most used to describe fluid balance are calculations from (1) cumulative fluid
inputs and outputs and (2) changes in measured body weight.49-55,57-72 The weight change method
has certain advantages because it accounts for unmeasured insensible losses, does not require an
invasive bladder catheter, and is less resource intensive. A weight-change method is preferred in
neonates to estimate fluid balance.58,73-77
Sick children are a heterogenous cohort of patients, and fluid overload may vary according to
patient-specific susceptibilities (eg, by patient age, case-mix, phase, or severity of illness). Thus, no
specific threshold can be recommended uniformly to define fluid overload in sick children.
Interventions to mitigate or treat fluid overload will need to be patient-specific and consider the
pathophysiologic context, the dynamics of the patient’s fluid balance, and the degree to which fluid
balance affects the severity of the patient’s fluid overload or volume depletion. eFigure 2 in the
Supplement provides a visual model of this precision approach (eBox and eBackground in the
Supplement).
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Workgroup 4: How Can Use of Kidney Support and Extracorporeal Therapies
in Children Be Advanced?
Consensus Statement 4A (Recommendation)
• A dedicated multidisciplinary team made up of kidney health care workers, patients, and families
along with institutional investments of personnel, time, materials, and quality assurance/
improvement systems are essential to a pediatric acute kidney support therapy (paKST) program.
Consensus Statement 4B (Suggestion)
• Patient-centered goals of care, degree of kidney recovery, physiological stability, fluid balance, and
global recovery and rehabilitation priorities inform decisions for de-escalation, liberation, transition,
and follow-up to optimize hospital-based and lifelong outcomes.
A paKST program requires thoughtful planning and synchronization across the health care enterprise
(eFigure 3 in the Supplement).28,78 Program development begins by identification of key
stakeholders with a vested interest in paKST delivery and outcomes. A multidisciplinary team of
kidney health care workers is responsible for fostering a culture of safety and transparency,
navigating organizational barriers, facilitating shared decision-making, providing education,
maintaining equipment, developing and maintaining policies, procedures, and guidelines, and
managing quality improvement data.28,78-84 Patients and families are vital partners, identifying goals
and advocating for effective and safe care. paKST device manufacturers and suppliers play an
important role in working with pediatric paKST providers to design products that can be used safely
and effectively in children, and to respond to the unique needs of a pediatric program. The care
delivery model should be based on available resources with representation from multiple
disciplines.28,78,79,82 Multiple blood purification and extracorporeal treatment modalities have been
developed (eTable 2 in the Supplement). Programs must define their standards of high-quality
delivery for the procedures they provide. Most quality metrics proposed by the ADQI XXII conference
are relevant for children.85 If a program is unable to provide high-quality care in a particular area, the
team must develop criteria and processes for transfer to an institution that provides such care, and
should examine the components lacking in their program to see if they can be addressed. The
education curriculum encompasses patient and team learning, is tailored to fit specific roles, and
includes competency assessments.28,78,80,86,87 Quality assurance or improvement systems should
be integrated into clinical practice, recognizing that cost, varied definitions, and lack of agreed-on
benchmarks are known barriers to implementation.28,78-80,82-84,88-92 Previous work by Rewa
et al80,89,90 and the 22nd ADQI conference28,80 has provided minimum programmatic standards
that may be used for paKST.
While most children who require paKST for AKI will achieve liberation from dialysis, there is
scant data to guide clinicians during kidney recovery.14,93-95 Current practices use estimates of the
ability to maintain euvolemia and metabolic balance for decisions about timing of paKST liberation,
transition, or de-escalation. Inability to execute timely transition from continuous paKST may
negatively affect outcomes, especially in light of emerging data on effectiveness of the ICU Liberation
Bundle.96-98 After paKST liberation, children are at risk for lifelong morbidity, including chronic
kidney disease, but guidance on optimal follow-up practices is lacking (eBox and eBackground in the
Supplement).3,99-101

Workgroup 5: How Do the Unique Pathobiology, Nutrition, and Pharmacology
of the Developing Child and AKI Need to Be Integrated?
Consensus Statement 5A (Recommendation)
• Successful pediatric translational AKI research programs include diverse teams using reverse
translational approaches in partnership with clinical and epidemiological findings that prioritize
development as a biologic variable. Sufficient support including pediatric specific government and
industry funding along with meaningful partnerships among health professionals is necessary to
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understand and leverage the unique aspects of pediatric AKI to address kidney health and disease
across the life course.
Consensus Statement 5B (Recommendation)
• Patient centered outcomes such as functional status, quality of life, and optimal growth and
development must drive the targeted nutritional interventions, optimizing short- and long-term
nutrition, and incorporate measures of acute and chronic changes of anthropometrics, body
composition, physical function, and metabolic control.
Engagement of diverse stakeholders across the preclinical and translational research realms is
needed to disseminate findings and transform care. Most translational AKI models do not account for
the additional complexity of pediatric AKI including the concept of development as a biologic variable
(DABV).102 The association between premature birth and kidney function and maturation remain
incompletely understood.103 Furthermore, the associations between a single AKI episode during
kidney development and short-term and long-term outcomes remain unclear.104 Potential sex
differences in AKI have prevented the inclusion of both males and females together in preclinical
animal studies. In pediatrics, sex as a biologic variable is further confounded by DABV; hormone
levels change throughout pubertal stages, and few clinical studies capture this information.105
Animal models of AKI that consider sex hormones and sex chromosomes could inform clinical
evaluations sensitive to sex as a biologic variable and DABV. The association between AKI and chronic
kidney disease has been established, however, there is a paucity of data on the systemic long-term
impact of AKI.106,107 The potential associations between AKI with respect to DABV and long-term
outcomes are unknown. Opportunities remain to use the unique aspects of pediatric patients,
including but not limited to the lack of chronic comorbidities and ability to understand the impact of
nephron endowment prior to nephron loss (Figure 231).
Malnutrition and protein energy wasting are prevalent and independently associated with
mortality in children hospitalized with AKI, especially those requiring paKST, with prevalence ranging
from 30% to 55%.108-111 Mortality is a crude end point to assess the importance of nutrition support
in children with AKI. AKI survivors are at risk of worsened functional status, chronic ventilation, or
dialysis after hospital discharge.111 Nutrition support and mobilization offer opportunities to improve
functional outcomes in survivors through attenuation of muscle loss and promotion of muscle
protein synthesis in critically ill children.112 The outcomes of malnutrition associated with somatic

Figure 2. Development as a Biologic Variable Related to Acute Kidney Injury
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The left slope highlights important developmental
stages critical to reach optimal kidney function. The right
slope represents the normal age-related decrease of
kidney function. Acute kidney injury (AKI) can occur at
any phase along the developmental trajectory resulting
in early kidney compromise and potentially accelerated
nephron loss. The timing and degree of AKI likely affect
the trajectory to recovery of normal kidney function or
persistently decreased function. Research efforts must
focus on uncovering and capitalizing on the ways to improve the outlook of an injured kidney. These efforts may
include optimization of nutrition, limiting further injury,
and novel therapeutics. There are factors that accelerate
nephron loss and the trajectory toward kidney failure.
The social determinants of health, the types or clusters
of AKI, sex as a biologic variable, nutritional factors, and
medication dosing are all components that affect the
recovery or decrease of kidney function after AKI.
Adapted from the 26th Acute Disease Quality Initiative31
with permission. These are open access images distributed under the terms of the Creative Commons
Attribution License.
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growth, body composition, development, immune function, metabolic derangements, and longterm physical and neurocognitive functioning require more precise measurement tools and
targets.113 Nutritional therapeutic interventions are nuanced and include changes in feeding
modality, composition (macronutrient or micronutrient) and volume of nutrition-related fluids which
intersects with medical AKI management and metabolic control, which can be further complicated
by institution of paKST. Nutritional needs are further affected by DABV.
Identifying and measuring appropriate outcome variables represent the first step to define the
phenotypic nutritional morbidities in pediatric AKI, and thereby enable evaluation of nutritional
intervention efficacy.114,115 We recommend program-based focused nutrition support for children
with AKI and transitioning through acute kidney disease.116 Such a program would use evidencebased nutrition therapy adjusted in response to changes in objectively measured nutrition-related
outcomes characterized by mitigating functional decline, a return to metabolic homeostasis, and
facilitation of long-term physical and neurocognitive rehabilitative processes.
Physiologic derangement in acute illness, with susceptibility factors of DABV render kidneyeliminated and nephrotoxic medication use uniquely complex in sick children. High-value
medications can be selected for detailed pharmacokinetic/pharmacodynamic/pharmaco-omics
characterization to inform drug disposition, dosing, and monitoring decisions at the bedside for AKI
and paKST (eBox and eBackground in the Supplement).117,118

Workgroup 6: Who Are the Key Stakeholders and What Is Required to Promote
Education and Advocacy for AKI in Children?
Consensus Statement 6A (Recommendation)
• Given the adverse immediate and lifelong outcomes for children with AKI, education and advocacy
are essential, starting with the patient and family and expanding across health care teams, systems,
and communities.
Consensus Statement 6B (Suggestion)
• Customized AKI education and advocacy require a comprehensive, multidisciplinary, and patient/
family centered focus, with AKI champions embedded at every level, embracing the complexities
of diverse settings and individuals, which need to evolve over the pediatric life span.
Education may address the widespread gaps in AKI recognition.119 Lack of AKI awareness may be
associated with disparities in AKI outcomes.120 Extending education to all stakeholders can reduce
the risk of missing AKI or delaying care.121 Because delayed changes in clinical markers (serum
creatinine level, urine output) may delay recognition of kidney injury, education requires awareness
of risk factors. Education must be delivered in varied settings, different backgrounds of health care
workers, and available resources with a flexible approach adjusted for the scenario and depth of
knowledge needed (Figure 331).
Education must include recognition of AKI risk, prevention and treatment of volume depletion,
careful attention to fluid balance, avoidance or limitation of nephrotoxic medications, and blood
pressure monitoring. Checklists, standardized screening and care protocols (care bundles), adapted
to and used across varied settings, can enhance identification of patients with or at risk for AKI.122
Successful education programs also require strong advocacy efforts to engage different constituents,
including patients and families, community members, physicians, allied health care professionals,
industry affiliates, and governmental and nongovernmental organizations (eTable 3 in the
Supplement). Education must be tailored to all members of the health care team, including patients
and family, and should occur on micro (individual learners, training program curriculum, teaching
modules, and alert systems for providers) and macro (health care system, communitywide
educational programs, and governmental policy) levels.
AKI education must be an integral part of the curriculum of foundational and advanced
education for all health care professionals, with continuing medical education for all practitioners.
Programs should view AKI as a core competency metric.121,123 Specialists in AKI (including educators,
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researchers, and advocates) must use educational methods for those who access online free openaccess medical education,124 available globally 24 hours per day. Patients and families may be
unaware of the AKI episode or of the potential for long-term adverse outcomes. AKI education may
help empower them to participate in healthy lifestyle modification and may improve follow-up,
which has the potential to improve long-term outcomes.125,126 Adaptable and multifaceted
educational tools, available in a variety of primary languages and for varying levels of health literacy,
should support comprehensive care from admission through discharge, follow-up and potentially,
readmission. Connectivity between patient and family with clinician may be essential in the AKI care
continuum.
AKI diagnosis remains a significant challenge across areas with varying resource availability
(low-income, war zones, and disaster areas), with the lack of appropriate laboratory supplies,
adequate medical infrastructure, and personnel. A recent survey emphasized the importance of

Figure 3. The Role of Education and Advocacy in Pediatric Acute Kidney Injury (AKI)
Education
Risk mitigation
Recognition and care
Guidelines

Science and
government
Health care
systems
Community

Child and
family
Implementation

Awareness

Equitable access to
diagnostics

Networks

Kidney protective care
across the lifespan

Metrics of kidney health

Integrated
collaborative care

Risk stratification

Technological innovation to
remove barriers

Advocacy

Education to improve AKI awareness and recognition in children rests on the pillar of
advocacy and must engage key stakeholders in developing multidisciplinary contextappropriate customized approaches to improve AKI care globally and across all resource
settings. Effective AKI education programs center the child and family, and expand
across health care teams, systems, and communities with champions embedded at every
level, health care systems, science, and government. AKI education must be a core
competency for health care clinicians to ensure that AKI risk mitigation measures are in
place to reduce AKI in community and hospital settings, to facilitate early recognition of

AKI through technological innovation, and to appropriately manage AKI using contextspecific guidelines that recognize the need for continuity of care and clinical follow-up.
Implementation of an effective AKI education and advocacy program assures equitable
access to diagnostics, emphasizes integrated multidisciplinary collaborative care, and
recognizes the unique long-term health outcomes of AKI in children across the life span.
Adapted from the 26th Acute Disease Quality Initiative31 with permission. These are
open access images distributed under the terms of the Creative Commons
Attribution License.
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involving and educating governments about the implications of AKI.127 Fostering partnerships with
industry and the international medical community will also be beneficial. Public-private partnerships
and programs may have established platforms that can be used for earlier diagnosis of AKI (eBox and
eBackground in the Supplement).128

Discussion
The pADQI consensus statements are expert-derived landscape definitions of the multifaceted and
multidisciplinary approach needed to improve prediction, diagnosis, management, and follow-up
care for AKI in children. The AKI story requires partnerships between patients and providers, across
the medical landscape and across the ages of children. We have provided recommendations for
current efforts and identified opportunities to address knowledge gaps (eBox in the Supplement).

Limitations
This study has limitations. The recommendations of the pADQI are based on existing evidence and
consensus but a systematic review on all individual studies and pieces of data was not performed. We
also acknowledge recent studies on AKI epidemiology, biomarkers, fluid accumulation, kidney
support therapy, nutrition, pharmacology, and education are in progress or have been completed
since the completion of pADQI and we could not account for their findings in our recommendations.

Conclusions
Nearly 2 decades of work in critical care nephrology has delivered a robust foundation on which to
frame future AKI education, advocacy, research, and clinical practice. AKI in children is unique and is
associated with long-lasting consequences. Improved outcomes in patients will require a
comprehensive and cross-discipline approach requiring stakeholders across medicine, community,
and government to partner with children and their families.

ARTICLE INFORMATION
Accepted for Publication: July 9, 2022.
Published: September 30, 2022. doi:10.1001/jamanetworkopen.2022.29442
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Goldstein
SL et al. JAMA Network Open.
Corresponding Author: Rajit K. Basu, MD, Division of Critical Care Medicine, Department of Pediatrics, Ann &
Robert Lurie Children’s Hospital of Chicago, Northwestern University School of Medicine, 225 E Chicago Ave, #73,
Chicago, IL 60611 (rkbasu@luriechildrens.org).
Author Affiliations: Center for Acute Care Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati,
Ohio (Goldstein, Devarajan, Gist, Hasson, J. Morgan, Stanski); Division of Critical Care Medicine and Nephrology,
Texas Children’s Hospital, Baylor College of Medicine, Houston (Akcan-Arikan); Alberta Health Sciences University,
Edmonton, Alberta, Canada (Alobaidi, Bagshaw, Ulrich, C. J. Morgan); Children’s Hospital Alabama, Birmingham
(Askenazi, Bjornstad); Ann & Robert Lurie Children’s Hospital of Chicago, Northwestern University, Chicago, Illinois
(Barhight, Mottes, Basu); Mayo Clinic, Rochester, Minnesota (Barreto); Department of Pediatric Intensive Care
Medicine, Life Support Center, Hacettepe University, Ankara, Turkey (Bayrakci); Nationwide Children’s Hospital,
The Ohio State University, Columbus (Bignall, Krawczeski); Golisano Children’s Hospital, Rochester University
Medical Center, Rochester, New York (Brophy); McMaster University, Hamilton, Ontario, Canada (Chanchlani);
University of Virginia, Charlottesville (Charlton); Riley Children’s Hospital, Indiana University, Bloomington
(Conroy, Soranno, Starr); King’s College London, London, United Kingdom (Deep); Mercy Children’s Hospital
Kansas City, Kansas City, Missouri (Dolan); Children’s Hospital of Pittsburgh, University of Pittsburgh Medical
Center, Pittsburgh, Pennsylvania (Fuhrman); C.S. Mott Children’s Hospital, University of Michigan, Ann Arbor
(Gorga); Yale University Medical Center, New Haven, Connecticut (Greenberg); St John’s Academy of Health
Sciences, Bangalore, Karnataka, India (Iyengar); Stead Family Children’s Hospital, The University of Iowa, Iowa City

JAMA Network Open. 2022;5(9):e2229442. doi:10.1001/jamanetworkopen.2022.29442 (Reprinted)

Downloaded From: https://jamanetwork.com/ on 10/31/2022

September 30, 2022

10/18

JAMA Network Open | Pediatrics

Recommendations on Priority Activities to Address Acute Kidney Injury in Children

(Jetton, Meigs); Seattle Children’s Hospital, Seattle, Washington (Menon, Symons); Washington University School
of Medicine, St Louis, Missouri (Neumayr); University of Florene, Florence, Italy (Ricci); Medical University of South
Carolina, Charleston (Selewski); Lucille Packard Children’s Hospital, Stanford University, Stanford, California
(Sutherland); Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil (Tavares); Division of Nephrology,
Texas Children’s Hospital, Baylor College of Medicine, Houston (Vega); The Hospital for Sick Children, Toronto,
Ontario, Canada (Zappitelli); Universiti di Padova, San Bartolo Hospital, Vicenza, Italy (Ronco); University of
California, San Diego Health Sciences, San Diego (Mehta); University of Pittsburgh Medical Center, Pittsburgh,
Pennsylvania (Kellum); Guys and St Thomas University, London, United Kingdom (Ostermann).
Author Contributions: Drs Goldstein and Basu had full access to all of the evidence used in the study and take
responsibility for the integrity and accuracy of the report.
Concept and design: Goldstein, Akcan-Arikan, Alobaidi, Bagshaw, Barhight, Barreto, Bayrakci, Brophy, Chanchlani,
Conroy, Deep, Dolan, Fuhrman, Gist, Greenberg, Krawczeski, Meigs, Menon, J. Morgan, C. Morgan, Selewski, Starr,
Stanski, Sutherland, Symons, Zappitelli, Ronco, Mehta, Kellum, Ostermann, Basu.
Acquisition, analysis, or interpretation of data: Askenazi, Bagshaw, Barhight, Bayrakci, Bignall, Bjornstad, Charlton,
Devarajan, Fuhrman, Gist, Gorga, Greenberg, Hasson, Ulrich, Iyengar, Jetton, Krawczeski, J. Morgan, C. Morgan,
Mottes, Neumayr, Ricci, Soranno, Starr, Stanski, Sutherland, Symons, Tavares, Wong Vega, Zappitelli, Kellum, Basu.
Drafting of the manuscript: Goldstein, Akcan-Arikan, Alobaidi, Bagshaw, Barhight, Barreto, Bayrakci, Bjornstad,
Brophy, Charlton, Conroy, Deep, Dolan, Fuhrman, Gist, Gorga, Greenberg, Ulrich, Jetton, Krawczeski, Menon, J.
Morgan, C. Morgan, Mottes, Neumayr, Ricci, Selewski, Soranno, Starr, Stanski, Sutherland, Symons, Wong Vega,
Zappitelli, Ostermann, Basu.
Critical revision of the manuscript for important intellectual content: Goldstein, Akcan-Arikan, Alobaidi, Askenazi,
Bagshaw, Barhight, Barreto, Bayrakci, Bignall, Bjornstad, Brophy, Chanchlani, Charlton, Deep, Devarajan, Fuhrman,
Gist, Gorga, Greenberg, Hasson, Ulrich, Iyengar, Jetton, Krawczeski, Meigs, Menon, C. Morgan, Neumayr, Ricci,
Selewski, Soranno, Starr, Stanski, Sutherland, Tavares, Wong Vega, Zappitelli, Ronco, Mehta, Kellum,
Ostermann, Basu.
Obtained funding: Goldstein, Ostermann, Basu.
Administrative, technical, or material support: Akcan-Arikan, Bagshaw, Barhight, Brophy, Deep, Greenberg, C.
Morgan, Mottes, Soranno, Tavares, Zappitelli, Mehta, Kellum, Ostermann, Basu.
Supervision: Goldstein, Akcan-Arikan, Askenazi, Bagshaw, Bayrakci, Brophy, Charlton, Devarajan, Gist, Greenberg,
Hasson, Ricci, Selewski, Ronco, Mehta, Basu.
Conflict of Interest Disclosures: Dr Goldstein reported receiving personal fees from BioPorto Diagnostics, grant
support and personal fees from Medtronic Inc, NuWellis Inc, Leadiant, personal fees from MediBeacon Inc, stock
options and personal fees from Baxter Healthcare, grant support and personal fees from SeaStar Medical, and
grants from ExThera Medical outside the submitted work. Dr Akcan-Arikan reported receiving financial support for
research from Bioporto research funds paid to her institution outside the submitted work. Dr Askenazi reported
receiving personal fees from Baxter, Nuwellis, Medtronic, Seastar, and Bioporto, and financial support for research
from Zorro-Flow outside the submitted work; in addition, Dr Askenazi reported having a patent for Zorro-Flow, an
external urine collection device pending, and a patent for continuous renal replacement therapy (CRRT)
advancements pending. Dr Bagshaw reported receiving personal fees from Baxter and BioPorto during the
conduct of the study. Dr Barreto reported receiving financial support for research from FAST Biomedical
Consultant and Wolters-Kluwer Consultant outside the submitted work. Dr Brophy reported receiving personal
fees from UpToDate during the conduct of the study and American Board of Medical Specialities finance board. Dr
Charlton reported receiving personal fees from Medtronics Carpediem Clinical Events Committee outside the
submitted work. Dr Devarajan reported receiving grants from National Institutes of Health/National Institute of
Diabetes and Digestive and Kidney Diseases during the conduct of the study; holding a patent as co-inventor on
patents licensed to Abbott Diagnostics and BioPorto Inc, on use of neutrophil gelatinase-associated lipocalin as a
biomarker of kidney injury. Dr Gist reported receiving financial support for research from Medtronic Speaker
Honorarium and financial support for research from Bioporto Diagnostics consulting fees outside the submitted
work. Dr Menon reported receiving personal fees from Nuwellis Inc outside the submitted work. Dr J. Morgan
reported receiving personal fees from Medtronic Consultant outside the submitted work. Dr Mottes reported
receiving financial support for research from Medtronic outside the submitted work. Dr Stanski reported receiving
grants from National Center for Advancing Translational Sciences of the National Institutes of Health Institutional
CT2 grant, 2UL1TR001425-05A1 and travel reimbursement from pADQI Travel funds to travel to consensus
meeting (flight and hotel) during the conduct of the study; in addition, Dr Stanski reported holding a patent for
PERSEVERE-II AKI Prediction Model pending. Dr Zappitelli reported receiving financial support for research from
Bioporto Inc adjudicator/consultant for a study on neutrophil gelatinase-associated lipocalin and financial support
for research from Baxter Inc Honorarium for a national talk on CRRT (not viewed by company ahead of time)
outside the submitted work. Dr Kellum reported receiving personal fees from Dialco; being an employee of
JAMA Network Open. 2022;5(9):e2229442. doi:10.1001/jamanetworkopen.2022.29442 (Reprinted)

Downloaded From: https://jamanetwork.com/ on 10/31/2022

September 30, 2022

11/18

JAMA Network Open | Pediatrics

Recommendations on Priority Activities to Address Acute Kidney Injury in Children

Spectral Medical and its wholly owned subsidiary Dialco outside the submitted work; and paid consultant for
Astute Medical. Dr Ostermann reported receiving grants from Fresenius Research funding, grants from Baxter
Research funding, and grants from Biomerieux Research funding during the conduct of the study. Dr Basu reported
receiving personal fees from Bioporto Diagnostics outside of the submitted work. and personal fees from
BioMerieux outside of the submitted work. during the conduct of the study; in addition, Dr Basu reported having a
patent for Renal Angina Index pending outside of the submitted work. and a patent for olfactomedin-4 pending
outside of the submitted work. No other disclosures were reported.
Funding/Support: The in-person meeting was supported by educational grants from AM Pharma, Baxter,
Biomerieux, BioPorto Diagnostics, Cincinnati Children’s Hospital, ExThera Medical, Leadiant, Lowell Therapeutics,
MediBeacon, Medtronic, Nuwellis, Potrero, Res Seminars, Seastar Medical, and Stavro Medical.
Role of the Funder/Sponsor: The funders had no involvement in the selection of the panelists, design or conduct
of the study; collection, management, analysis, or interpretation of the data; preparation, review, and approval of
the manuscript; and decision to submit the manuscript for publication. Representatives from the funders were
present at the face-to-face meeting but did not participate in the panel discussions, voting, or final decisions.
Group Information: All authors are members of the Pediatric ADQI Collaborative.
REFERENCES
1. Kaddourah A, Basu RK, Bagshaw SM, Goldstein SL; AWARE Investigators. Epidemiology of acute kidney injury
in critically ill children and young adults. N Engl J Med. 2017;376(1):11-20. doi:10.1056/NEJMoa1611391
2. Jetton JG, Boohaker LJ, Sethi SK, et al; Neonatal Kidney Collaborative (NKC). Incidence and outcomes of
neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study. Lancet Child
Adolesc Health. 2017;1(3):184-194. doi:10.1016/S2352-4642(17)30069-X
3. Robinson CH, Jeyakumar N, Luo B, et al. Long-term kidney outcomes following dialysis-treated childhood acute
kidney injury: a population-based cohort study. J Am Soc Nephrol. 2021;32(8):2005-2019. doi:10.1681/ASN.
2020111665
4. Greenberg JH, Zappitelli M, Devarajan P, et al; TRIBE-AKI Consortium. Kidney outcomes 5 years after pediatric
cardiac surgery: The TRIBE-AKI Study. JAMA Pediatr. 2016;170(11):1071-1078. doi:10.1001/jamapediatrics.
2016.1532
5. Madsen NL, Goldstein SL, Frøslev T, Christiansen CF, Olsen M. Cardiac surgery in patients with congenital heart
disease is associated with acute kidney injury and the risk of chronic kidney disease. Kidney Int. 2017;92(3):
751-756. doi:10.1016/j.kint.2017.02.021
6. Akcan-Arikan A, Gebhard DJ, Arnold MA, Loftis LL, Kennedy CE. Fluid overload and kidney injury score:
a multidimensional real-time assessment of renal disease burden in the critically ill patient. Pediatr Crit Care Med.
2017;18(6):524-530. doi:10.1097/PCC.0000000000001123
7. Abbasi A, Mehdipour Rabori P, Farajollahi R, et al. Discriminatory precision of renal angina index in predicting
acute kidney injury in children; a systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8(1):e39.
8. Gist KM, Goldstein SL, Wrona J, et al. Kinetics of the cell cycle arrest biomarkers (TIMP-2*IGFBP-7) for prediction
of acute kidney injury in infants after cardiac surgery. Pediatr Nephrol. 2017;32(9):1611-1619. doi:10.1007/s00467017-3655-y
9. Menon S, Goldstein SL, Mottes T, et al. Urinary biomarker incorporation into the renal angina index early in
intensive care unit admission optimizes acute kidney injury prediction in critically ill children: a prospective cohort
study. Nephrol Dial Transplant. 2016;31(4):586-594. doi:10.1093/ndt/gfv457
10. Goldstein SL, Vidal E, Ricci Z, et al. Survival of infants treated with CKRT: comparing adapted adult platforms
with the Carpediem™. Pediatr Nephrol. 2022;37(3):667-675. doi:10.1007/s00467-021-05180-y
11. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup. Acute renal
failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the
Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;
8(4):R204-R212. doi:10.1186/cc2872
12. Mehta RL, Kellum JA, Shah SV, et al; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an
initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. doi:10.1186/cc5713
13. Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in
critically ill children with acute kidney injury. Kidney Int. 2007;71(10):1028-1035. doi:10.1038/sj.ki.5002231
14. Kidney International Supplements. KDIGO clinical practice guideline for acute kidney injury. March 2012.
Accessed July 27, 2022. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf

JAMA Network Open. 2022;5(9):e2229442. doi:10.1001/jamanetworkopen.2022.29442 (Reprinted)

Downloaded From: https://jamanetwork.com/ on 10/31/2022

September 30, 2022

12/18

JAMA Network Open | Pediatrics

Recommendations on Priority Activities to Address Acute Kidney Injury in Children

15. Fitzgerald JC, Basu RK, Akcan-Arikan A, et al; Sepsis PRevalence, OUtcomes, and Therapies Study Investigators
and Pediatric Acute Lung Injury and Sepsis Investigators Network. Acute kidney injury in pediatric severe sepsis:
an independent risk factor for death and new disability. Crit Care Med. 2016;44(12):2241-2250. doi:10.1097/CCM.
0000000000002007
16. Menon S, Kirkendall ES, Nguyen H, Goldstein SL. Acute kidney injury associated with high nephrotoxic
medication exposure leads to chronic kidney disease after 6 months. J Pediatr. 2014;165(3):522-7.e2. doi:10.1016/
j.jpeds.2014.04.058
17. Uber AM, Montez-Rath ME, Kwiatkowski DM, Krawczeski CD, Sutherland SM. Nephrotoxin exposure and acute
kidney injury in critically ill children undergoing congenital cardiac surgery. Pediatr Nephrol. 2018;33(11):
2193-2199. doi:10.1007/s00467-018-4010-7
18. Blinder JJ, Asaro LA, Wypij D, et al. Acute kidney injury after pediatric cardiac surgery: a secondary analysis of
the safe pediatric euglycemia after cardiac surgery trial. Pediatr Crit Care Med. 2017;18(7):638-646. doi:10.1097/
PCC.0000000000001185
19. Hessey E, Morissette G, Lacroix J, et al. Healthcare utilization after acute kidney injury in the pediatric intensive
care unit. Clin J Am Soc Nephrol. 2018;13(5):685-692. doi:10.2215/CJN.09350817
20. Sutherland SM, Ji J, Sheikhi FH, et al. AKI in hospitalized children: epidemiology and clinical associations in a
national cohort. Clin J Am Soc Nephrol. 2013;8(10):1661-1669. doi:10.2215/CJN.00270113
21. Hessey E, Perreault S, Dorais M, Roy L, Zappitelli M. Acute kidney injury in critically ill children and subsequent
chronic kidney disease. Can J Kidney Health Dis. 2019;6:2054358119880188. doi:10.1177/2054358119880188
22. Bjornstad EC, Marshall SW, Mottl AK, et al. Racial and health insurance disparities in pediatric acute kidney
injury in the USA. Pediatr Nephrol. 2020;35(6):1085-1096. doi:10.1007/s00467-020-04470-1
23. Hodgson LE, Selby N, Huang TM, Forni LG. The role of risk prediction models in prevention and management
of AKI. Semin Nephrol. 2019;39(5):421-430. doi:10.1016/j.semnephrol.2019.06.002
24. Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by implementing the
KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive
Care Med. 2017;43(11):1551-1561. doi:10.1007/s00134-016-4670-3
25. Fleming GM, Sahay R, Zappitelli M, et al. The incidence of acute kidney injury and its effect on neonatal and
pediatric extracorporeal membrane oxygenation outcomes: a multicenter report from the Kidney Intervention
During Extracorporeal Membrane Oxygenation Study Group. Pediatr Crit Care Med. 2016;17(12):1157-1169. doi:10.
1097/PCC.0000000000000970
26. Blinder JJ, Goldstein SL, Lee VV, et al. Congenital heart surgery in infants: effects of acute kidney injury on
outcomes. J Thorac Cardiovasc Surg. 2012;143(2):368-374. doi:10.1016/j.jtcvs.2011.06.021
27. Sutherland SM, Byrnes JJ, Kothari M, et al. AKI in hospitalized children: comparing the pRIFLE, AKIN, and
KDIGO definitions. Clin J Am Soc Nephrol. 2015;10(4):554-561. doi:10.2215/CJN.01900214
28. Selewski DT, Askenazi DJ, Kashani K, et al. Quality improvement goals for pediatric acute kidney injury:
pediatric applications of the 22nd Acute Disease Quality Initiative (ADQI) conference. Pediatr Nephrol. 2021;36
(4):733-746. doi:10.1007/s00467-020-04828-5
29. Zappitelli M, Moffett BS, Hyder A, Goldstein SL. Acute kidney injury in non-critically ill children treated with
aminoglycoside antibiotics in a tertiary healthcare centre: a retrospective cohort study. Nephrol Dial Transplant.
2011;26(1):144-150. doi:10.1093/ndt/gfq375
30. Sandokji I, Yamamoto Y, Biswas A, et al. A time-updated, parsimonious model to predict AKI in hospitalized
children. J Am Soc Nephrol. 2020;31(6):1348-1357. doi:10.1681/ASN.2019070745
31. Acute Disease Quality Initiative. Images. 2020. Accessed July 30, 2022. https://www.adqi.org/Images
32. Kashani K, Rosner MH, Haase M, et al. Quality improvement goals for acute kidney injury. Clin J Am Soc
Nephrol. 2019;14(6):941-953. doi:10.2215/CJN.01250119
33. Schunk SJ, Zarbock A, Meersch M, et al. Association between urinary dickkopf-3, acute kidney injury, and
subsequent loss of kidney function in patients undergoing cardiac surgery: an observational cohort study. Lancet.
2019;394(10197):488-496. doi:10.1016/S0140-6736(19)30769-X
34. Bennett MR, Pyles O, Ma Q, Devarajan P. Preoperative levels of urinary uromodulin predict acute kidney injury
after pediatric cardiopulmonary bypass surgery. Pediatr Nephrol. 2018;33(3):521-526. doi:10.1007/s00467-0173823-0
35. Fuhrman DY, Nguyen L, Hindes M, Kellum JA. Baseline tubular biomarkers in young adults with congenital
heart disease as compared to healthy young adults: detecting subclinical kidney injury. Congenit Heart Dis. 2019;
14(6):963-967. doi:10.1111/chd.12862

JAMA Network Open. 2022;5(9):e2229442. doi:10.1001/jamanetworkopen.2022.29442 (Reprinted)

Downloaded From: https://jamanetwork.com/ on 10/31/2022

September 30, 2022

13/18

JAMA Network Open | Pediatrics

Recommendations on Priority Activities to Address Acute Kidney Injury in Children

36. Husain-Syed F, Ferrari F, Sharma A, et al. Preoperative renal functional reserve predicts risk of acute kidney
injury after cardiac operation. Ann Thorac Surg. 2018;105(4):1094-1101. doi:10.1016/j.athoracsur.2017.12.034
37. Parikh CR, Coca SG, Thiessen-Philbrook H, et al; TRIBE-AKI Consortium. Postoperative biomarkers predict
acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol. 2011;22(9):1748-1757. doi:10.
1681/ASN.2010121302
38. McCullough PA, Bouchard J, Waikar SS, et al. Implementation of novel biomarkers in the diagnosis, prognosis,
and management of acute kidney injury: executive summary from the tenth consensus conference of the Acute
Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2013;182:5-12. doi:10.1159/000349962
39. Basu RK, Wong HR, Krawczeski CD, et al. Combining functional and tubular damage biomarkers improves
diagnostic precision for acute kidney injury after cardiac surgery. J Am Coll Cardiol. 2014;64(25):2753-2762. doi:
10.1016/j.jacc.2014.09.066
40. Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalinpositive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol.
2011;57(17):1752-1761. doi:10.1016/j.jacc.2010.11.051
41. Stanski N, Menon S, Goldstein SL, Basu RK. Integration of urinary neutrophil gelatinase-associated lipocalin
with serum creatinine delineates acute kidney injury phenotypes in critically ill children. J Crit Care. 2019;53:1-7.
doi:10.1016/j.jcrc.2019.05.017
42. Kaddourah A, Basu RK, Goldstein SL, Sutherland SM; Assessment of Worldwide Acute Kidney Injury, Renal
Angina and, Epidemiology (AWARE) Investigators. Oliguria and acute kidney injury in critically ill children:
implications for diagnosis and outcomes. Pediatr Crit Care Med. 2019;20(4):332-339. doi:10.1097/PCC.
0000000000001866
43. Sutherland SM, Kaddourah A, Gillespie SE, et al; Assessment of the Worldwide Acute Kidney Injury, Renal
Angina and Epidemiology (AWARE) Investigators. Cumulative application of creatinine and urine output staging
optimizes the kidney disease: improving global outcomes definition and identifies increased mortality risk in
hospitalized patients with acute kidney injury. Crit Care Med. 2021;49(11):1912-1922. doi:10.1097/CCM.
0000000000005073
44. Basu RK, Hackbarth R, Gillespie S, et al. Clinical phenotypes of acute kidney injury are associated with unique
outcomes in critically ill septic children. Pediatr Res. 2021;90(5):1031-1038. doi:10.1038/s41390-021-01363-3
45. Gist KM, Borasino S, SooHoo M, et al. Transient and persistent acute kidney injury phenotypes following the
Norwood operation: a retrospective study. Cardiol Young. 2022;32(4):564-571. doi:10.1017/S1047951121002560
46. Gist KM, Selewski DT, Brinton J, Menon S, Goldstein SL, Basu RK. Assessment of the independent and
synergistic effects of fluid overload and acute kidney injury on outcomes of critically ill children. Pediatr Crit Care
Med. 2020;21(2):170-177. doi:10.1097/PCC.0000000000002107
47. Borasino S, Wall KM, Crawford JH, et al. Furosemide response predicts acute kidney injury after cardiac
surgery in infants and neonates. Pediatr Crit Care Med. 2018;19(4):310-317. doi:10.1097/PCC.
0000000000001478
48. Penk J, Gist KM, Wald EL, et al. Furosemide response predicts acute kidney injury in children after cardiac
surgery. J Thorac Cardiovasc Surg. 2019;157(6):2444-2451. doi:10.1016/j.jtcvs.2018.12.076
49. Goldstein SL, Currier H, Graf Cd, Cosio CC, Brewer ED, Sachdeva R. Outcome in children receiving continuous
venovenous hemofiltration. Pediatrics. 2001;107(6):1309-1312. doi:10.1542/peds.107.6.1309
50. Goldstein SL, Somers MJ, Baum MA, et al. Pediatric patients with multi-organ dysfunction syndrome receiving
continuous renal replacement therapy. Kidney Int. 2005;67(2):653-658. doi:10.1111/j.1523-1755.2005.67121.x
51. Gorga SM, Sahay RD, Askenazi DJ, et al. Fluid overload and fluid removal in pediatric patients on extracorporeal
membrane oxygenation requiring continuous renal replacement therapy: a multicenter retrospective cohort study.
Pediatr Nephrol. 2020;35(5):871-882. doi:10.1007/s00467-019-04468-4
52. Hassinger AB, Wald EL, Goodman DM. Early postoperative fluid overload precedes acute kidney injury and is
associated with higher morbidity in pediatric cardiac surgery patients. Pediatr Crit Care Med. 2014;15(2):131-138.
doi:10.1097/PCC.0000000000000043
53. Hayes LW, Oster RA, Tofil NM, Tolwani AJ. Outcomes of critically ill children requiring continuous renal
replacement therapy. J Crit Care. 2009;24(3):394-400. doi:10.1016/j.jcrc.2008.12.017
54. Hazle MA, Gajarski RJ, Yu S, Donohue J, Blatt NB. Fluid overload in infants following congenital heart surgery.
Pediatr Crit Care Med. 2013;14(1):44-49. doi:10.1097/PCC.0b013e3182712799
55. Sutherland SM, Zappitelli M, Alexander SR, et al. Fluid overload and mortality in children receiving continuous
renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney
Dis. 2010;55(2):316-325. doi:10.1053/j.ajkd.2009.10.048

JAMA Network Open. 2022;5(9):e2229442. doi:10.1001/jamanetworkopen.2022.29442 (Reprinted)

Downloaded From: https://jamanetwork.com/ on 10/31/2022

September 30, 2022

14/18

JAMA Network Open | Pediatrics

Recommendations on Priority Activities to Address Acute Kidney Injury in Children

56. Hoste EA, Maitland K, Brudney CS, et al; ADQI XII Investigators Group. Four phases of intravenous fluid
therapy: a conceptual model. Br J Anaesth. 2014;113(5):740-747. doi:10.1093/bja/aeu300
57. Alobaidi R, Basu RK, DeCaen A, et al. Fluid accumulation in critically ill children. Crit Care Med. 2020;48(7):
1034-1041.
58. Askenazi DJ, Koralkar R, Hundley HE, Montesanti A, Patil N, Ambalavanan N. Fluid overload and mortality are
associated with acute kidney injury in sick near-term/term neonate. Pediatr Nephrol. 2013;28(4):661-666. doi:
10.1007/s00467-012-2369-4
59. Bontant T, Matrot B, Abdoul H, et al. Assessing fluid balance in critically ill pediatric patients. Eur J Pediatr.
2015;174(1):133-137. doi:10.1007/s00431-014-2372-9
60. Foland JA, Fortenberry JD, Warshaw BL, et al. Fluid overload before continuous hemofiltration and survival in
critically ill children: a retrospective analysis. Crit Care Med. 2004;32(8):1771-1776. doi:10.1097/01.CCM.
0000132897.52737.49
61. Li Y, Wang J, Bai Z, et al. Early fluid overload is associated with acute kidney injury and PICU mortality in
critically ill children. Eur J Pediatr. 2016;175(1):39-48. doi:10.1007/s00431-015-2592-7
62. Lima L, Menon S, Goldstein SL, Basu RK. Timing of fluid overload and association with patient outcome.
Pediatr Crit Care Med. 2021;22(1):114-124. doi:10.1097/PCC.0000000000002547
63. Lombel RM, Kommareddi M, Mottes T, et al. Implications of different fluid overload definitions in pediatric
stem cell transplant patients requiring continuous renal replacement therapy. Intensive Care Med. 2012;38(4):
663-669. doi:10.1007/s00134-012-2503-6
64. Mallory PP, Selewski DT, Askenazi DJ, et al. Acute kidney injury, fluid overload, and outcomes in children
supported with extracorporeal membrane oxygenation for a respiratory indication. ASAIO J. 2020;66(3):319-326.
doi:10.1097/MAT.0000000000001000
65. Michael M, Kuehnle I, Goldstein SL. Fluid overload and acute renal failure in pediatric stem cell transplant
patients. Pediatr Nephrol. 2004;19(1):91-95. doi:10.1007/s00467-003-1313-z
66. Selewski DT, Cornell TT, Blatt NB, et al. Fluid overload and fluid removal in pediatric patients on extracorporeal
membrane oxygenation requiring continuous renal replacement therapy. Crit Care Med. 2012;40(9):2694-2699.
doi:10.1097/CCM.0b013e318258ff01
67. Selewski DT, Cornell TT, Lombel RM, et al. Weight-based determination of fluid overload status and mortality
in pediatric intensive care unit patients requiring continuous renal replacement therapy. Intensive Care Med. 2011;
37(7):1166-1173. doi:10.1007/s00134-011-2231-3
68. Sinitsky L, Walls D, Nadel S, Inwald DP. Fluid overload at 48 hours is associated with respiratory morbidity but
not mortality in a general PICU: retrospective cohort study. Pediatr Crit Care Med. 2015;16(3):205-209. doi:10.
1097/PCC.0000000000000318
69. Valentine SL, Sapru A, Higgerson RA, et al; Pediatric Acute Lung Injury and Sepsis Investigator’s (PALISI)
Network; Acute Respiratory Distress Syndrome Clinical Research Network (ARDSNet). Fluid balance in critically ill
children with acute lung injury. Crit Care Med. 2012;40(10):2883-2889. doi:10.1097/CCM.0b013e31825bc54d
70. Selewski DT, Askenazi DJ, Bridges BC, et al. The impact of fluid overload on outcomes in children treated with
extracorporeal membrane oxygenation: a multicenter retrospective cohort study. Pediatr Crit Care Med. 2017;18
(12):1126-1135. doi:10.1097/PCC.0000000000001349
71. Barhight MF, Brinton J, Stidham T, et al. Increase in chloride from baseline is independently associated with
mortality in critically ill children. Intensive Care Med. 2018;44(12):2183-2191. doi:10.1007/s00134-018-5424-1
72. Barhight MF, Brinton JT, Soranno DE, Faubel S, Mourani PM, Gist KM. Effects of hyperchloremia on renal
recovery in critically ill children with acute kidney injury. Pediatr Nephrol. 2020;35(7):1331-1339. doi:10.1007/
s00467-020-04513-7
73. Selewski DT, Gist KM, Nathan AT, et al; Neonatal Kidney Collaborative. The impact of fluid balance on
outcomes in premature neonates: a report from the AWAKEN study group. Pediatr Res. 2020;87(3):550-557. doi:
10.1038/s41390-019-0579-1
74. Selewski DT, Akcan-Arikan A, Bonachea EM, et al; Neonatal Kidney Collaborative. The impact of fluid balance
on outcomes in critically ill near-term/term neonates: a report from the AWAKEN study group. Pediatr Res.
2019;85(1):79-85. doi:10.1038/s41390-018-0183-9
75. Starr MC, Charlton JR, Guillet R, et al; Neonatal Kidney Collaborative Board. Advances in neonatal acute kidney
injury. Pediatrics. 2021;148(5):e2021051220. doi:10.1542/peds.2021-051220
76. van Asperen Y, Brand PL, Bekhof J. Reliability of the fluid balance in neonates. Acta Paediatr. 2012;101(5):
479-483. doi:10.1111/j.1651-2227.2012.02591.x

JAMA Network Open. 2022;5(9):e2229442. doi:10.1001/jamanetworkopen.2022.29442 (Reprinted)

Downloaded From: https://jamanetwork.com/ on 10/31/2022

September 30, 2022

15/18

JAMA Network Open | Pediatrics

Recommendations on Priority Activities to Address Acute Kidney Injury in Children

77. Schmidt B, Roberts RS, Fanaroff A, et al; TIPP Investigators. Indomethacin prophylaxis, patent ductus
arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin
Prophylaxis in Preterms (TIPP). J Pediatr. 2006;148(6):730-734. doi:10.1016/j.jpeds.2006.01.047
78. Mottes TA. CRRT Program Development. Critical Care Nephrology and Renal Replacement Therapy in Children.
Springer; 2018:357-368. doi:10.1007/978-3-319-90281-4_23
79. Mottes TA, Goldstein SL, Basu RK. Process based quality improvement using a continuous renal replacement
therapy dashboard. BMC Nephrol. 2019;20(1):17. doi:10.1186/s12882-018-1195-8
80. Rewa OG, Tolwani A, Mottes T, et al. Quality of care and safety measures of acute renal replacement therapy:
workgroup statements from the 22nd acute disease quality initiative (ADQI) consensus conference. 2019;54:5257.
81. Mottes TA. Does your program know its AKI and CRRT epidemiology? the case for a dashboard. Front Pediatr.
2020;8:80. doi:10.3389/fped.2020.00080
82. Askenazi D, Basu RK. Kidney support therapy in the pediatric patient: Unique considerations for a unique
population. Semin Dial. 2021;34(6):530-536. doi:10.1111/sdi.12978
83. Harer MW, Selewski DT, Kashani K, et al. Improving the quality of neonatal acute kidney injury care: neonatalspecific response to the 22nd Acute Disease Quality Initiative (ADQI) conference. J Perinatol. 2021;41(2):185-195.
doi:10.1038/s41372-020-00810-z
84. Neyra JA, Kashani K. Improving the quality of care for patients requiring continuous renal replacement
therapy. Semin Dial. 2021;34(6):501-509. doi:10.1111/sdi.12968
85. Rewa OG, Tolwani A, Mottes T, et al; ADQI Consensus Meeting Members on behalf of ADQI XXII. Quality of care
and safety measures of acute renal replacement therapy: workgroup statements from the 22nd acute disease
quality initiative (ADQI) consensus conference. J Crit Care. 2019;54:52-57. doi:10.1016/j.jcrc.2019.07.003
86. Przybyl H, Androwich I, Evans J. Using high-fidelity simulation to assess knowledge, skills, and attitudes in
nurses performing CRRT. Nephrol Nurs J. 2015;42(2):135-147.
87. Richardson A, Whatmore J. Nursing essential principles: continuous renal replacement therapy. Nurs Crit
Care. 2015;20(1):8-15. doi:10.1111/nicc.12120
88. Mottes T, Owens T, Niedner M, Juno J, Shanley TP, Heung M. Improving delivery of continuous renal
replacement therapy: impact of a simulation-based educational intervention. Pediatr Crit Care Med. 2013;14(8):
747-754. doi:10.1097/PCC.0b013e318297626e
89. Rewa O, Villeneuve PM, Eurich DT, et al. Quality indicators in continuous renal replacement therapy (CRRT)
care in critically ill patients: protocol for a systematic review. Syst Rev. 2015;4:102. doi:10.1186/s13643-015-0088-1
90. Rewa OG, Eurich DT, Noel Gibney RT, Bagshaw SM. A modified Delphi process to identify, rank and prioritize
quality indicators for continuous renal replacement therapy (CRRT) care in critically ill patients. J Crit Care. 2018;
47:145-152. doi:10.1016/j.jcrc.2018.06.023
91. Shen B, Xu J, Wang Y, Jiang W, Teng J, Ding X. Continuous renal replacement therapy quality control and
performance measures. Contrib Nephrol. 2018;194:134-145. doi:10.1159/000485611
92. Ruiz EF, Ortiz-Soriano VM, Talbott M, et al; University of Kentucky CRRT Quality Assurance Group.
Development, implementation and outcomes of a quality assurance system for the provision of continuous renal
replacement therapy in the intensive care unit. Sci Rep. 2020;10(1):20616. doi:10.1038/s41598-020-76785-w
93. Uchino S, Bellomo R, Morimatsu H, et al. Discontinuation of continuous renal replacement therapy: a post hoc
analysis of a prospective multicenter observational study. Crit Care Med. 2009;37(9):2576-2582. doi:10.1097/
CCM.0b013e3181a38241
94. Fröhlich S, Donnelly A, Solymos O, Conlon N. Use of 2-hour creatinine clearance to guide cessation of
continuous renal replacement therapy. J Crit Care. 2012;27(6):744.e1-744.e5. doi:10.1016/j.jcrc.2012.08.012
95. Schiffl H, Lang SM. Current approach to successful liberation from renal replacement therapy in critically ill
patients with severe acute kidney injury: the quest for biomarkers continues. Mol Diagn Ther. 2021;25(1):1-8. doi:
10.1007/s40291-020-00498-z
96. Pun BT, Balas MC, Barnes-Daly MA, et al. Caring for critically ill patients with the ABCDEF Bundle: results of the
ICU Liberation Collaborative in over 15,000 adults. Crit Care Med. 2019;47(1):3-14. doi:10.1097/CCM.
0000000000003482
97. Barnes-Daly MA, Phillips G, Ely EW. Improving hospital survival and reducing brain dysfunction at seven
California community hospitals: implementing PAD guidelines via the ABCDEF bundle in 6,064 patients. Crit Care
Med. 2017;45(2):171-178. doi:10.1097/CCM.0000000000002149

JAMA Network Open. 2022;5(9):e2229442. doi:10.1001/jamanetworkopen.2022.29442 (Reprinted)

Downloaded From: https://jamanetwork.com/ on 10/31/2022

September 30, 2022

16/18

JAMA Network Open | Pediatrics

Recommendations on Priority Activities to Address Acute Kidney Injury in Children

98. Hopkins RO, Choong K, Zebuhr CA, Kudchadkar SR. Transforming PICU culture to facilitate early rehabilitation.
J Pediatr Intensive Care. 2015;4(4):204-211. doi:10.1055/s-0035-1563547
99. Starr MC, Hingorani SR. Prematurity and future kidney health: the growing risk of chronic kidney disease. Curr
Opin Pediatr. 2018;30(2):228-235. doi:10.1097/MOP.0000000000000607
100. Lebel A, Teoh CW, Zappitelli M. Long-term complications of acute kidney injury in children. Curr Opin
Pediatr. 2020;32(3):367-375. doi:10.1097/MOP.0000000000000906
101. Hessey E, Melhem N, Alobaidi R, et al. Acute kidney injury in critically ill children is not all acute: lessons over
the last 5 years. Front Pediatr. 2021;9:648587. doi:10.3389/fped.2021.648587
102. Hukriede NA, Soranno DE, Sander V, et al. Experimental models of acute kidney injury for translational
research. Nat Rev Nephrol. 2022;18(5):277-293. doi:10.1038/s41581-022-00539-2
103. Charlton JR, Baldelomar EJ, Hyatt DM, Bennett KM. Nephron number and its determinants: a 2020 update.
Pediatr Nephrol. 2021;36(4):797-807. doi:10.1007/s00467-020-04534-2
104. Askenazi DJ, Morgan C, Goldstein SL, et al. Strategies to improve the understanding of long-term renal
consequences after neonatal acute kidney injury. Pediatr Res. 2016;79(3):502-508. doi:10.1038/pr.2015.241
105. Bairey Merz CN, Dember LM, Ingelfinger JR, et al; participants of the National Institute of Diabetes and
Digestive and Kidney Diseases Workshop on “Sex and the Kidneys”. Sex and the kidneys: current understanding
and research opportunities. Nat Rev Nephrol. 2019;15(12):776-783. doi:10.1038/s41581-019-0208-6
106. Sato Y, Takahashi M, Yanagita M. Pathophysiology of AKI to CKD progression. Semin Nephrol. 2020;40(2):
206-215. doi:10.1016/j.semnephrol.2020.01.011
107. Selewski DT, Hyatt DM, Bennett KM, Charlton JR. Is acute kidney injury a harbinger for chronic kidney
disease? Curr Opin Pediatr. 2018;30(2):236-240. doi:10.1097/MOP.0000000000000587
108. Castillo A, Santiago MJ, López-Herce J, et al. Nutritional status and clinical outcome of children on continuous
renal replacement therapy: a prospective observational study. BMC Nephrol. 2012;13:125. doi:10.1186/1471-236913-125
109. Lion RP, Vega MR, Smith EO, et al. The effect of continuous venovenous hemodiafiltration on amino acid
delivery, clearance, and removal in children. Pediatr Nephrol. 2022;37(2):433-441. doi:10.1007/s00467-02105162-0
110. Vega MW, Juarez M, Lee JY, Srivaths P, Williams E, Akcan Arikan A. Quality improvement bedside rounding
audits enhance protein provision for pediatric patients receiving continuous renal replacement therapy. Pediatr
Crit Care Med. 2018;19(11):1054-1058. doi:10.1097/PCC.0000000000001698
111. Smith M, Bell C, Vega MW, et al. Patient-centered outcomes in pediatric continuous kidney replacement
therapy: new morbidity and worsened functional status in survivors. Pediatr Nephrol. 2022;37(1):189-197. doi:10.
1007/s00467-021-05177-7
112. Abraham AG, Mak RH, Mitsnefes M, et al. Protein energy wasting in children with chronic kidney disease.
Pediatr Nephrol. 2014;29(7):1231-1238. doi:10.1007/s00467-014-2768-9
113. Rees L. Protein energy wasting; what is it and what can we do to prevent it? Pediatr Nephrol. 2021;36(2):
287-294. doi:10.1007/s00467-019-04424-2
114. Verbruggen SC, Schierbeek H, Coss-Bu J, Joosten KF, Castillo L, van Goudoever JB. Albumin synthesis rates in
post-surgical infants and septic adolescents; influence of amino acids, energy, and insulin. Clin Nutr. 2011;30(4):
469-477. doi:10.1016/j.clnu.2011.02.001
115. Malagaris I, Herndon DN, Polychronopoulou E, et al. Determinants of skeletal muscle protein turnover
following severe burn trauma in children. Clin Nutr. 2019;38(3):1348-1354. doi:10.1016/j.clnu.2018.05.027
116. Chawla LS, Bellomo R, Bihorac A, et al; Acute Disease Quality Initiative Workgroup 16. Acute kidney disease
and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev
Nephrol. 2017;13(4):241-257. doi:10.1038/nrneph.2017.2
117. Rodieux F, Wilbaux M, van den Anker JN, Pfister M. Effect of kidney function on drug kinetics and dosing in
neonates, infants, and children. Clin Pharmacokinet. 2015;54(12):1183-1204. doi:10.1007/s40262-015-0298-7
118. Nguyen TTL, Liu D, Ho MF, Athreya AP, Weinshilboum R. Selective serotonin reuptake inhibitor
pharmaco-omics: mechanisms and prediction. Front Pharmacol. 2021;11:614048. doi:10.3389/fphar.2020.
614048
119. McGregor TL, Jones DP, Wang L, et al. Acute kidney injury incidence in noncritically ill hospitalized children,
adolescents, and young adults: a retrospective observational study. Am J Kidney Dis. 2016;67(3):384-390. doi:10.
1053/j.ajkd.2015.07.019

JAMA Network Open. 2022;5(9):e2229442. doi:10.1001/jamanetworkopen.2022.29442 (Reprinted)

Downloaded From: https://jamanetwork.com/ on 10/31/2022

September 30, 2022

17/18

JAMA Network Open | Pediatrics

Recommendations on Priority Activities to Address Acute Kidney Injury in Children

120. Macedo E, Cerdá J, Hingorani S, et al. Recognition and management of acute kidney injury in children: the ISN
0by25 Global Snapshot study. PLoS One. 2018;13(5):e0196586. doi:10.1371/journal.pone.0196586
121. Liu KD, Goldstein SL, Vijayan A, et al; AKI!Now Initiative of the American Society of Nephrology. AKI!Now
initiative: recommendations for awareness, recognition, and management of AKI. Clin J Am Soc Nephrol. 2020;15
(12):1838-1847. doi:10.2215/CJN.15611219
122. Macedo E, Hemmila U, Sharma SK, et al; ISN 0by25 Trial Study Group. Recognition and management of
community-acquired acute kidney injury in low-resource settings in the ISN 0by25 trial: a multi-country feasibility
study. PLoS Med. 2021;18(1):e1003408. doi:10.1371/journal.pmed.1003408
123. National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and
management: NICE Guideline [NG148]. 2019. Accessed July 27, 2022. https://www.nice.org.uk/guidance/ng148
124. Colbert GB, Topf J, Jhaveri KD, et al. The social media revolution in nephrology education. Kidney Int Rep.
2018;3(3):519-529. doi:10.1016/j.ekir.2018.02.003
125. Silver SA, Goldstein SL, Harel Z, et al. Ambulatory care after acute kidney injury: an opportunity to improve
patient outcomes. Can J Kidney Health Dis. 2015;2:36. doi:10.1186/s40697-015-0071-8
126. Harel Z, Wald R, Bargman JM, et al. Nephrologist follow-up improves all-cause mortality of severe acute
kidney injury survivors. Kidney Int. 2013;83(5):901-908. doi:10.1038/ki.2012.451
127. Lunyera J, Kilonzo K, Lewington A, Yeates K, Finkelstein FO. Acute kidney injury in low-resource settings:
barriers to diagnosis, awareness, and treatment and strategies to overcome these barriers. Am J Kidney Dis. 2016;
67(6):834-840. doi:10.1053/j.ajkd.2015.12.018
128. Finkelstein FO, Smoyer WE, Carter M, Brusselmans A, Feehally J. Peritoneal dialysis, acute kidney injury, and
the Saving Young Lives program. Perit Dial Int. 2014;34(5):478-480. doi:10.3747/pdi.2014.00041
SUPPLEMENT.
eBackground. Group Descriptions
eBox. Research Agenda for Pediatric Acute Kidney Injury
eFigure 1. An Evolving Approach to AKI Epidemiology
eTable 1. Definitions of Fluid Balance
eFigure 2. The Spectrum of Fluid Balance
eFigure 3. Multipronged Approach to Pediatric Acute Kidney Support Therapy
eTable 2. Blood Purification and Extracorporeal Treatment Modalities for Different Pathophysiological Conditions
eTable 3. Key Components of Education and Advocacy for Children With Acute Kidney Injury (AKI)

JAMA Network Open. 2022;5(9):e2229442. doi:10.1001/jamanetworkopen.2022.29442 (Reprinted)

Downloaded From: https://jamanetwork.com/ on 10/31/2022

September 30, 2022

18/18

